Jointly configured by ICON experts and building on Intel's AI and analytics leadership, trials that leverage the Intel® Pharma Analytics Platform can:
- Capture de-identified, objective, high-quality, rich sensory data via sensors and wearable devices.
- Get real-time information about protocol adherence while helping patients manage medication, perform structured tests and report symptoms.
- Utilize smartphone applications to collect electronic diaries and patient reported outcomes (PROs).
- Transmit the de-identified data to a secured cloud infrastructure for storage and analysis.
- Apply machine learning and other AI methods to objectively assess and quantify the severity of symptoms, quantify the impact of therapies such as medication efficacy or dose response.
The Intel® Pharma Analytics Platform provides benefits for pharmaceutical companies seeking to speed and simplify clinical trials, reduce trial costs, and gather more objective evidence; by transitioning to automatic collection of consistent, unbiased data, remote monitoring for data analysis, and delivering improved patient experience. These changes will help accelerate time-to-market for new drugs, by producing high-quality data and increasing patient retention, leading to shorter trials.
Intel values individuals' privacy and employs technical and organizational measures where appropriate to protect the privacy and security of the personal data of the users of the Intel® Pharma Analytics Platform, as required by Articles 28 and 32 GDPR and any other applicable laws. Where appropriate, Intel performs data protection impact assessments as required under Article 35 GDPR.
"Our engagement with Intel confirms ICON's position as the leading CRO
for advancing the use of wearable technology, and will expand ICON's
existing offering to include a service where data can be aggregated and
analysed from mhealth and wearable technologies, with advanced analytics
allowing for development of novel endpoints and digital biomarkers,"
"Intel is accelerating the pace of digital transformation, and IT plays
a leading role in delivering solutions on that journey," says
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in
+44 (0)207 067 0557
News Provided by Acquire Media